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CObjective: To evaluate the cost-effectiveness of introducing the RTS,S
malaria vaccine into the Expanded Programme on Immunization (EPI)
in Sub-Saharan Africa (SSA), the contributions of different sources of
uncertainty, and the associated expected value of perfect information
(EVPI).Methods: Vaccination was simulated in populations of 100,000
eople at 10 different entomological inoculation rates (EIRs), using an
xisting stochastic model and a 10-year time horizon. Incremental
ost-effectiveness ratios (ICERs) and EVPI were computed from
eighted averages of outputs using two different assignments of the
IR distribution in 2007. Uncertainty was evaluated by resampling of
pidemiological, vaccination, and health systems model parameters.
esults: Health benefits were predicted consistently only at low trans-
mission, and program costs always substantially exceeded case man-
agement savings. Optimal cost-effectiveness was at EIR of about 10
infectious bites per annum (ibpa). Main contributors to ICER uncer-
tainty were uncertainty in transmission intensity, price per vaccine O
miol
al So
oi:10.1016/j.jval.2011.06.004ose, decay rate of the vaccine effect, degree of homogeneity in host
esponse, and some epidemiological model parameters. Other health
ystem costs were unimportant. With a ceiling ratio of 207 interna-
ional dollars per disability-adjusted life-year averted, 52.4% of param-
terizations predicted cost-effectiveness in the primary analysis.
onclusions: Cost-effectiveness of RTS,S will bemaximal in low ende-
icity settings (EIR 2-20 ibpa). Widespread deployment of other trans-
ission-reducing interventions will thus improve cost-effectiveness,
uggesting a selective introduction strategy. EVPI is substantial. Ac-
rual of up-to-date information on local endemicity to guide deploy-
ent decisions would be highly efficient.
eywords: cost-effectiveness, expected value of perfect information,
alaria, probabilistic sensitivity analysis, vaccine.
opyright © 2011, International Society for Pharmacoeconomics and
utcomes Research (ISPOR). Published by Elsevier Inc.Introduction
The RTS,S vaccine against Plasmodium falciparum malaria is cur-
rently close to licensure, having demonstrated moderate levels
of efficacy in several phase II trials in Africa [1]. RTS,S is a pre-
erythrocytic vaccine, meaning that it modifies the risk that a
human host becomes infected when he or she is bitten by an
infectious mosquito. Analysis of the initial field trial data led to
an estimate that a full course of vaccination prevents 52% of
new infections [2], but that no one is completely protected
against infection (the vaccine is ”leaky”). Even leaky malaria
vaccines of moderate efficacy may be of value, given that ma-
laria was the eighth highest contributor to the global burden of
disease in 2001 (2.9% of total global disability-adjusted life-
years [DALYs]) [3].
There have been several analyses of both likely effectiveness
[4–6] and cost-effectiveness [7,8] of RTS,S deployment using
stochastic models of malaria epidemiology, which agree that
the disease burden averted and cost-effectiveness will be highly
* Address correspondence to: Thomas Smith, Department of Epide
ocinstrasse 57, 4051 Basel, Switzerland.
E-mail: Thomas-A.Smith@unibas.ch.
098-3015/$36.00 – see front matter Copyright © 2011, Internation
ublished by Elsevier Inc.dependent on the transmission setting [4–6]. This article uses
estimates of cost-effectiveness from the previously described
models [7] but adds two important elements. First, it extends
the analyses to consider uncertainties in the parameters of the
epidemiological or case-management models, in the effects of
the vaccine, or in costs. Standard techniques of probabilistic
sensitivity analysis, involving randomly sampling the parame-
ter vectors, are used to analyze the contributions of the differ-
ent sources of uncertainty to the ICERs. One specific aspect of
these analyses of uncertainty is quantification of the value of
acquiring additional information on these parameters by com-
puting the theoretical value of complete information about
them (expected value of perfect information, [EVPI] [9]). Al-
though EVPI has only recently been applied in health sector
evaluations relevant to low- and middle-income countries [10],
this analysis is highly pertinent to decisions of whether to de-
ploy RTS,S.
The second extension is to link the cost-effectiveness to es-
timates of the distribution of levels of malaria transmission in
the places where RTS,S might be introduced to predict overall
ogy and Public Health, Swiss Tropical and Public Health Institute,
ciety for Pharmacoeconomics and Outcomes Research (ISPOR).
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1029V A L U E I N H E A L T H 1 4 ( 2 0 1 1 ) 1 0 2 8 – 1 0 3 8ICERs for introducing RTS,S via the Expanded Programme on
Immunization (EPI) across Sub-Saharan Africa (SSA). Because
the distribution of malaria exposure (the entomological inocu-
lation rate [EIR], whichmeasures exposure to the infective stage
of the parasite) across SSA is also uncertain, we present a sen-
sitivity analysis considering two different hypothesized distri-
butions of the EIR of African populations.
Methods
Epidemiological model
The natural history and epidemiology of P. falciparum were sim-
lated using a stochastic simulation model described in detail
n an open-access supplement to the American Journal of Tropical
edicine and Hygiene [11–16]. The simulated human populations
sed an age structure based on Ifakara, Tanzania [17]. At each
tep, new births were introduced and “removal” of simulated
eople was carried out to mimic deaths. Some of the deaths are
alaria related, but additional “removals” were simulated to
aintain a stable population size and more or less stationary
ge distribution [11]. A consequence of the dynamics of immu-
ity and of the cohort effect resulting from the numbers of peo-
le immunized building up over time is that the effects (per-
entage of episodes averted) vary over time.
This model was fitted to field data from a variety of settings
cross SSA [18]. As in the original publications, the model was
easonally forced using the pattern of the vectorial capacity in
amawala, Tanzania, scaled to give 10 different values of the
nitial exposures ranging from an EIR of 2.1 infectious bites per
erson per annum (ibpa) to 420 ibpa. Pathogenesis and case
anagement (including hospital treatment of severe cases) was
lso simulated, as described in the original implementation
12,13,19], but the simulated first-line treatment was changed
rom sulfadoxine-pyrimethamine (SP) to artemether-lumefan-
rine (AL) [5]. Thus, any changes in transmission intensity in-
uced by the vaccination program (including any herd immu-
ity effects) were simulated, but the vectorial capacity followed
he same annual cycle as in the absence of vaccine.
Pre-erythrocytic vaccination was also simulated as de-
cribed previously [4,5], assuming that vaccination leads to a
eduction in the proportion of inoculations from the bites of
nfected mosquitoes that lead to blood stage infection and that
he vaccine efficacy is assumed to be equal to the proportion by
hich this force of infection is reduced. This is substantially
igher than the efficacy in preventing clinical episodes [2]. A
entral value of 0.6 was used for the distribution of efficacy of a
ull course of vaccine. This is somewhat higher than the value of
.52 that best explained the results of initial trials using the
S02 adjuvant [2]. More recent trials with the AS01 adjuvant
ave reported somewhat higher efficacy values than the earlier
nes. The current clinical development plan of RTS,S assumes
hat it will be introduced into routine immunization of infants
ia the EPI. In keeping with this, simulated delivery of the vac-
ine was at ages 1, 2, and 3 months with full vaccination cover-
ge (three doses) of 89% and a dropout rate from the first dose to
he third dose of 6% [4]. Vaccine coverage is assumed to be
eached instantaneously, and vaccine efficacy is achieved im-
ediately after vaccination.
The health outcomes simulated were uncomplicated epi-
odes, severe episodes, and deaths, translated to DALYs [20].
ase fatality rates followed a nonmonotonic function of age
ased on East African data [12]. Expert opinions were elicited for
he probability of neurological sequelae [7]. Consistent with
lobal Burden of Disease and WHO-CHOICE methodology [21],
he calculation of DALYs did not include age weighting but did
nclude 3% per annum discounting, irrespective of whether the vanalysis used discounting by the time of the event. The same
disability weights and Ethiopian life table were used for calcu-
lating DALYs as in our previous analyses [19].
Each simulation was run with a total population of 100,000
humans and separately for the 10 different EIR values. Effective-
ness results were generated by running the model for a 10-year
time horizon, starting from steady-state populations and com-
paring status quo simulated populations with case manage-
ment (as described previously), with simulations with the same
initial transmission levels and case management coverage but
with vaccination in addition.
Costs
A societal perspective including provider perspective costs, and
out-of-pocket patient costs was used for costing, using adapting
values for Tanzania from our previous study [7]. This included
both vaccination and case management components. Forty per-
cent of incremental costs are nontraded based on the break-
down of outpatient, drug, hospital care, and patient costs [7].
Nontraded costs were inflated according to a Tanzanian rate,
and traded costs were inflated according to a US rate. To correct
for purchasing power disparities, costs are presented as 2008
international dollars (I$) calculated as described in WHO-
CHOICE [22].
Vaccination and health service use costs (Table 1) were based
on those of the original analysis with these models [19], but were
updated by changing the simulated first-line treatment from SP to
AL [23], and adding the cost of microscopy for diagnosis (including
both materials and staff time) [24]. Freight costs, wastage rates
(15%), storage, and management costs of the program were also
based on those used previously [19].
Population distribution of EIR
A geostatistical model developed by the Malaria Atlas Project
(MAP) for prevalence of malaria [25] was used to estimate the
EIR distribution for the potentially vaccinated population in Af-
rica. This model provided georeferenced model-based esti-
mates of prevalence, pˆ, in children aged 2 to 10 years for the year
2007, and hence the formal analyses are based on the assump-
tion that prevalence remains similar to this. True prevalence p
is substantially more variable than pˆ because the spatially
smoothed geostatistical model estimates exclude nonspatial
extrabinomial variation. To avoid biased estimation of average
levels of transmission and underestimation of geographic vari-
ation clearly evident in transmission maps that do not allow for
this [26], the extent of this extrabinomial variation was esti-
mated by comparing the pˆ values to raw prevalence data.
Prevalence determinations for age 2 to 10 years from the open-
access Mapping Malaria Risk in Africa database were summarized
by year and location to obtain a total of 1446 year- and location-
specific prevalence values, where prevalence point i corresponds
to ni parasite-positive individuals among Ni total children sur-
veyed, for each of which a geographically matched value, pˆi could
e found on the MAP surface. The hierarchical model
i  Binomial(Ni, p˜) (1)
og p˜i(1 p˜i)  Normallog pˆi(1 pˆi),12 (2)
as used to compare the two data sets, where the SD 1 measures
xtrabinomial variation. This model was fitted using WinBUGS
1.4 software [27]. Alternative models allowing for interdatabase
1030 V A L U E I N H E A L T H 1 4 ( 2 0 1 1 ) 1 0 2 8 – 1 0 3 8Table 1 – Model parameters and distributions.
Symbol Description of parameter Units Central
value
V1 V2 Distrib. Ref. Ranking
Model of natural history and epidemiology
S Lower limit of success probability of
inoculations at high Ea(i,t)
Proportion 0.049 0.270 — A [16] 25
E* Critical value of Ea(i,t) Inoculations/
person-night
0.032 0.126 — B [16] 20
Simm Lower limit of success probability of
inoculations in immune individuals
Proportion 0.145 0.037 — B [16] 43
p Steepness of relationship between
success of inoculation and Xp(i,t)
Dimensionless 2.061 0.176 — B [16] 29
X*p Critical value of cumulative no. of
entomological inoculations
Inoculations 2801.5 0.025 — B [16] 16
X*h Critical value of cumulative no. of
infections
Infections 97.8 0.808 — B [16] 1
X*y Critical value of cumulative no. of
parasite days
Parasite-days/L 1.38  107 0.094 — B [16] 45
X*v Critical value of cumulative no. of
infections for variance in parasite
densities
Infections 0.918 0.058 — B [16] 24
m Maternal protection at birth Proportion 0.900 0.058 — A [16] 30
*m Decay of maternal protection Per year 2.587 0.042 — B [16] 14
2i Variation between individuals in
densities
Dimensionless 9.570 0.025 — B [11] 32
20 Fixed variance component for densities [ln(parasites/)]
2 0.657 0.097 — B [16] 49
 Factor determining increase in Y*(i,t) Parasites2 2
day1
1.57  105 0.165 — B [16] 9
 Decay rate of pyrogenic threshold Year1 0.279 0.091 — B [16] 21
Y*0 Pyrogenic threshold at birth Parasites/ 328.1 2.350 — B [16] 11
Y*1 Critical value of parasite density in
determining increase in Y*
Parasites/ 0.601 0.600 — B [16] 15
Y*2 Critical value of Y*(i,t) in determining
increase in Y*(i,t)
Parasites/ 9696.3 0.116 — B [16] 12
Y*B1 Parasitemia threshold for severe
episodes type B1
Parasites/ 3.47  105 0.200 — B [16] 19
F0 Prevalence of comorbidity/susceptibility
at birth relevant to severe episodes
(B2)
Proportion 0.099 0.145 — B [16] 10
*F Critical age for comorbidity Years 0.116 0.158 — B [16] 5
1 Case fatality for severe episodes in the
community compared to hospital
ln(odds ratio) 0.729 0.515 — B [16] 8
O˛n Nonmalaria intercept for infant
mortality rate
Deaths/1000 live
births
50.6 0.203 — B [16] 35
O˛D Comorbidity intercept relevant to
indirect mortality
Proportion 0.018 0.334 — B [16] 4
Treatment seeking for uncomplicated malaria
Pu % of fever patients seeking care in the
formal health sector
% in a time step 4.0 2.8 5.2 C [19] 22
Ps % self-treatment % in a time step 1.0 0.7 1.3 C [19] 28
Pr % seeking outpatient care in case of
treatment failure
% in a time step 4.0 2.8 5.2 C [19,61] 48
phc % of outpatient visits that take place at
health centers
% 18 — —- D [61] —
pd % of outpatient visits that take place at
dispensaries
% 72 — — D [61] —
ph % of outpatient visits that take place at
hospitals
% 10 — — D [61] —
pt % of diagnostic tests (proportion of
patients): Tanzania
% 51 38 72 C [34] 44
pro % of outpatient visit costs that are
recurrent
% 69 — — D [62,63] —
prfo % of outpatient visit recurrent costs that
are fixed
% 31 25 40 C [63] 46(continued on next page)
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Symbol Description of parameter Units Central
value
V1 V2 Distrib. Ref. Ranking
Adherence and cure rate: uncomplicated malaria
Cu Adherence % 75 59 90 C [38–40] 28
Cr Cure rate (ACT)
† % 85 78 95 C [64,65] 37
Cs % of nonadherent patients for whom
treatment is effective
% 0 — — D [66,67] 47
Case management: severe malaria
Ph % patients obtaining inpatient care % 48 19 88 C [66,68–70] 13
Rq Cure rate (quinine)* % 80 70 90 C [22,71] 50
Rx1 % of neurological sequelae for severe
episodes for age group 5 years†
% 3.5 2.0 5.0 C ‡ 17
Rx2 % of neurological sequelae for severe
episodes for age-group 5 years†
% 1.5 1.0 2.0 C ‡ 33
prfi % of recurrent inpatient costs that are
fixed
% 63 60 75 C [66] 38
Li1 Average length of stay when patient
fully recovers
Days 4.5 — — D [72, 73] —
Li2 Average length of stay when patient has
neurological sequelae
Days 10 —- — D [67] —
Li3 Average length of stay when patient
dies
Days 2 — — D [67,72,73] —
Characteristics of the vaccine
	1 Vaccine efficacy after dose 1 Proportion 0.12 0 0.24 C [2] 23
	2 Vaccine efficacy after dose 2 Proportion 0.36 0.24 0.48 C [2] 42
	3 Vaccine efficacy after dose 3 Proportion 0.6 0.48 0.72 C [2] 6
t1/2 Vaccine half-life Years 10 0.789 — B [4] 3
b Vaccine homogeneity Dimensionless 10 1.5 — B [2] 7
Unit costs of management of uncomplicated malaria
Va ACT: cost per tablet (including 25%
wastage)
I$ 0.14 0.13 0.19 E [37] 41
Vhc Cost per outpatient visit at health
centers
I$ 2.89 1.27 7.90 E [22,74] 26
Vd Cost per outpatient visit at dispensaries I$ 2.64 1.02 7.65 E [22,74] 39
Vh Cost per outpatient visit at hospitals I$ 4.39 2.35 13.91 E [62] 36
Tm Unit cost of field standard microscopy I$ per slide 0.58 0.45 1.34 E [75] 51
Unit costs of management of severe malaria
Vq Quinine dihydrochloride cost I$/2-mL
ampoule (300
mg/mL)
0.10 0.02 0.55 E [37] 27
Ni Nondrug cost (total) I$/day of stay 15.99 8.54 20.86 E [22,76] 31
Unit costs of vaccine provision
Vv Vaccine price I$/dose 5 2 10 E — 2
Vvc Cold chain storage and distribution I$/dose 0.11 0.09 0.13 E [77] 34
Vvd Vaccine delivery (recurrent, personnel,
nonrecurrent)
I$/dose 0.20 0.16 0.24 E [77] 18
Vvt Training (recurrent and fixed) I$/dose 0.03 0.02 0.04 E [77] 40
A, Sampled from a log normal distributionwith SD V1 after transformation of the central value (p) into a positive real value using xln(1 p); B,
Sampled from a log normal distribution with standard deviation V1; C, Sampled from a beta approximation to the triangular distribution defined by
the central value, minimum V1 and maximum V2; D, Treated as fixed (not sampled); E, Sample from a log normal approximation to the triangular
distribution defined by the central value, minimum V1 andmaximum V2.
* The cure rate refers to the adequate clinical response rate.
† The same probabilities are used for neurological sequelae for both inpatients and nonhospitalized severe episodes.
‡ Whitty and Greenwood, personal communication, 2005.
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1032 V A L U E I N H E A L T H 1 4 ( 2 0 1 1 ) 1 0 2 8 – 1 0 3 8and interyear variation were also fitted. All thesemodels provided
nearly identical estimates of 1  1.77.
For each value of pˆ(rounded to the nearest 1%), a sample of
00,000 values of p was drawn using Eq. 2. An empirical analysis
Fig. 1 – Distributions of the entomological inoculation rate
EIR). A, Estimated distribution of exposure for 2007 across
ub-Saharan Africa (SSA). B. Adjusted distribution in which
ll EIRs <1.05 infectious bites per annum (ibpa) are shifted
nto a single category centered at 1.05 ibpa (hatched column).
he areas of the solid columns correspond to the proportions
f the population of SSA assigned to each EIR category.
Table 2 – Summary of cost-effectiveness estimated from th
EIR (infectious bites
per annum)
DALYs averted
Discounted Undiscounted D
0.131 754.1 901.0
0.263 1508.2 1801.9
0.525 3016.5 3603.9
1.05 6032.9 7207.8
2.1 12,065.9 14,415.6
5.25 14,602.9 17,542.6
10.5 10,662.2 12,896.9
21 10,776.7 12,758.9
42 8982.4 10,464.6
84 6656.6 7586.0
168 1201.2 1259.6
252 1287.3 1977.9
336 2560.7 3524.0
420 7263.1 8750.6
* Discounting both costs and benefits.
† Discounting neither costs nor benefits.28] suggests that EIR can be related to prevalence by relationships
f the form:
(j)  Normal0,22 (3)
E(j) exp01p˜(j)
(j) (4)
with parameter estimates 0  1.2419, 1  7.3066, and 
2
2 (D.
mith, personal communication, October 2010). Corresponding to
he jth sampled p value, p(j), a value of E(j) was sampled from the
istribution of the EIR.
The LandScan Global Population Database [29] was used to
btain the proportion of the population assigned to each per-
entage point of the distribution of pˆ (Fig. 1A), and these propor-
ions were used to weight the values of E(j) to provide a Monte
arlo estimate of the distribution of the EIR. This distribution
as binned into 15 categories, corresponding to EIR ranges cen-
ered on the 10 EIR values in the simulations, and an additional
ve lower EIR values centered on EIRs of 1.05 ibpa, 0.525 ibpa,
.263 ibpa, 0.131 ibpa, and 0.066 ibpa (distribution A). A sensi-
ivity analysis was carried out using an alternative EIR distribu-
ion because the true assignment of low-exposure sites to EIR
ategories is highly uncertain and themodel did not use data for
uch settings [28]. Distribution B (Fig. 1B) was constructed by
rouping all EIRs falling into any of the five lowest categories
nto a single bin centered on EIR 1.05 ibpa.
Cost-effectiveness
Net costs and numbers of DALYs averted were calculated by com-
puting pairwise differences in costs and DALYs between vaccina-
tion and status quo (nonvaccination) scenarios. Incremental cost-
effectiveness ratios (ICERs) were then calculated as the ratio of net
costs to DALYs averted and related to a range of decision thresh-
olds using cost-effectiveness acceptability curves (CEACs) [30].
Analyseswere carried out separatelywith undiscounted costs and
with costs discounted at 3% per annum [31]. In addition, we con-
sidered the effect of discounting health benefits (also at 3% per
annum (Table 2). For each EIR category, the ICER was computed by
dividing the incremental cost by the incremental benefit (inDALYs
averted) per capita, multiplied by the total population at risk (Ta-
ble 2).
se model.
cost (I$, thousands) ICER (I$/DALY averted)
nted Undiscounted Discounted* Undiscounted†
.3 1127.7 1065.8 1495.4
.0 1125.0 531.7 745.9
.5 1119.5 264.6 371.1
.6 1108.5 131.1 183.7
.6 1086.5 64.3 90.1
.0 1076.8 52.3 73.7
.2 1084.3 71.7 101.7
.5 1089.1 72.7 101.1
.9 1107.5 90.0 123.3
.5 1122.6 125.8 168.6
.8 1146.8 773.9 954.7
.0 1158.2 — —
.3 1158.4 — —
.2 1166.4 — —e ba
Net
iscou
960
958
953
944
926
918
924
927
941
954
974
984
984
991
1033V A L U E I N H E A L T H 1 4 ( 2 0 1 1 ) 1 0 2 8 – 1 0 3 8In the absence of malaria, vaccination would not avert any
illness, and at very low transmission, infection events can be
treated as independent of each other, so the number of DALYs
averted and case management cost savings are directly propor-
tional to EIR. ICERs for the EIR values 2.1 ibpa were thus com-
puted from the results of the simulations at EIR 2.1 ibpa (assum-
ing proportionality to EIR), whereas vaccination costs remained
equal to those at EIR 2.1.
The overall ICER for each parameterization was obtained using
a weighted average according to proportions of a population as-
signed to each EIR category. In determining cost-effectiveness, a
range of ceiling ratios was considered, with particular emphasis
on values of I$207 per DALY, corresponding to the 1993 World
Development Report proposal of $150, defined according to the
“minimum care package” of services thought to be affordable in
low- and middle-income countries. The value of I$207 per DALY
was obtained by inflation adjustment to the year 2008 using rates
obtained from OANDA Corporation (www.OANDA.com). A ceiling
ratio of I$2008 was also used, equal to the 2008 Gross Domestic
Product (GDP) per capita for SSA based on the WHO-CHOICE proj-
ect [22].
Uncertainty/sensitivity analysis
Estimation of the probability that vaccinationwill be cost-effective
required rerunning of the simulations using resampled values of
both epidemiological and health-system parameters [32]. The ep-
idemiological parameters were transformed into the real positive
line and independently sampled from log-normal distributions
with means and SDs matched to the point estimates and confi-
dence intervals estimated from the original fitting process.
Health-system parameters and costs were assigned distribu-
tions based on available evidence (Table 1). This required reviews
of literature from SSA on cost and frequency of diagnosis in Tan-
zania [33–36], direct costs of care including drugs [37], and patient
adherence to prescribed regimens [38–41]. WHO-CHOICE ranges
were used according to different levels of coverage for hospital
costs and outpatient visits [22]. Uncertainty around other param-
eters was based on percentages specified by expert opinion, in-
cluding probability of seeking care (30%), vaccine delivery costs
(20%), and household (patient) costs (10%). Vaccine price (cen-
tered on I$5, with a lower limit of I$1 and an upper limit of I$10,
was based on discussions involving potential program funders.
Freight costs,wastage rates, storage, andmanagement costs of the
program were not sampled. Remaining parameters and ranges
were based on Goodman et al. [24]. The health-system parameters
were also sampled independently of each other, with beta distri-
butions used to represent uncertainty around probabilities and
log-normal distributions for costs.
Each simulated scenario was run separately for each EIR with
each of the 1000 sampled parameterizations both with and with-
out vaccination. Probabilities that a vaccination programwould be
cost-effective were estimated by the proportions of these param-
eterizations for which the ICER was less than each of a series of
ceiling ratios. Acceptability curves were constructed by plotting
these proportions against the ceiling ratio.
Regression analysis of the ICERs as functions of the sampled
parameter values were used to estimate the contributions of the
different parameters to the uncertainty. For each parameter, the
contribution to uncertainty was measured by the difference be-
tween the ICER predicted at the 2.5 and 97.5 percentiles of the
sampled distribution. Plots of these differences in rank order (tor-
nado diagrams) were used to indicate which variables contribute
the most uncertainty.
Discontinuity of ICERs around the axes of the cost-effective-
ness plane is a recognized issue in such analyses [42]. Scenarios
with small cost savings due to the intervention have very different
ICERs from those with small positive costs, even if the health ef-fects are similar, and this can invalidate analyses of untrans-
formed ICERs. In this study, however, cost savings due to the in-
tervention were never observed, so it was sufficient to treat
negative ICERs (which arose in a few simulations because of neg-
ative effectiveness) as positive values above the ceiling ratio.
To quantify the value of acquiring additional information on
the parameters, we computed the theoretical value of complete
information about them (EVPI [9]), using the algorithm described
in the Appendix on the uncertainty in the ICER and EVPI found at
doi:10.10.106/j.jval.2011.06.004.
Results
At low and moderate levels of transmission, both the base case
simulations (Table 2) and almost all the resampled parameteriza-
tions suggested that a vaccination program would have overall
health benefits over the 10-year time horizon (Fig. 2), but with
considerable variability in predicted cost and effectiveness. The
Fig. 2 – Cost-effectiveness planes. Each circle corresponds
to one parameterization. The four panels correspond to the
lowest of the 15 entomological inoculation rate (EIR) values
analyzed (for which the data were obtained by
interpolation) (A); the lowest EIR simulated (B); an
intermediate EIR (C), and a high EIR (D). The diagonal lines
correspond to ceiling ratios of international dolloars (I$)
207 per disability-adjusted life-year (DALY) averted (less
steep lines) and I$2008 per DALY averted (steeper lines).
Net costs and DALYs averted are computed for a simulated
population of 100,000 people with discounting.cost of the program was always considerably more than the case
1034 V A L U E I N H E A L T H 1 4 ( 2 0 1 1 ) 1 0 2 8 – 1 0 3 8management savings, so costs were more than those in the status
quo scenario, corresponding to positive net costs of the vaccina-
tion program. At the very lowest EIR considered, malaria is a rare
disease, so the effectiveness is always close to zero (Fig. 2A). At an
EIR of 2.1 ibpa (Fig. 2B), many ICERs were lower than the ceiling
ratio of I$207 per DALY averted, indicated by the less steep diago-
nal lines on the figures. All ICERs were to the right of the steeper,
nearly vertical, lines on the figures corresponding to the GDP-
based ceiling ratio of I$2008 per DALY averted.
At the highest levels of transmission, many simulations pre-
dicted very low or negative health benefits (Fig. 2C,D); the incre-
mental effectiveness of the vaccination program greatly de-
creased with EIR (Fig. 3). This applied when considering either the
best-fitting parameterization, the median of the simulations, or
results for all 1000 parameterizations. Spearman correlations be-
tween the ICER predicted in the simulations and the EIR were posi-
tive for all but 4 of the 1000 parameterizations. Discounting of costs
(or benefits) made little difference to the overall pattern of these re-
sults. The remainder of the analyses presented here considered only
scenarios with discounting of costs but not of benefits.
The interpolated ICERs computed for the lowest transmission
settings were not included in the analysis of correlations with EIR
and suggest a trend opposite to that of higher EIRs, implying that
there is a minimum value of ICER of approximately 10 ibpa. This
minimum translates into a maximum in the curves of the proba-
bility cost-effective by EIR computed from the full set of ICERs for
a range of ceiling ratios (Fig. 4).
When the ICER was computed as a weighted average over the
15 EIR categories, the reference parameterization gave an ICER of
145.2 I$/DALY averted for EIR distribution A and an ICER of 111.7
I$/DALY averted for EIR distribution B. Over the whole set of pa-
rameterizations, distribution A gave a median ICER of 200.1 I$/
DALY averted (interquartile range, 130.9–314.4), whereas distribu-
tion B gave a median ICER of 157.9 I$/DALY (interquartile range,
106.1–240.6). Acceptability curves (Fig. 5) for the two EIR distribu-
Fig. 3 – Incremental cost-effectiveness ratio (ICER) by
transmission intensity. The envelope encloses the
interquartile range for 1000 simulations. Values for
entomological inoculation rate (EIR) <2.1 infectious bites
per annum (ibpa) (to the left of the vertical dashed line) are
based on interpolation between EIR 0 and EIR 2.1 ibpa.
Undiscounted costs (A); discounted costs (B).tions are similar overmost of the range, but diverge over the range
of reasonable ceiling ratios. At a ceiling ratio of I$207 per DALY
averted, 65.9% of parameterizations predicted cost-effectiveness
with distribution A and 52.4% of parameterizations are cost-effec-
tive with distribution B. At the ceiling ratio of I$2008, all but one
parameterization predict cost-effectiveness with both distribu-
tions (thiswas a parameterization that predicted a negative health
benefit).
The contributions of the different parameters to uncertainty in
the ICERwere analyzed bymultiple linear regression of the ICER as
a function of each of the sampled parameters. The resulting pa-
rameter estimates were used to compute the fitted ICER for the 2.5
Fig. 4 – Probability that the vaccination program is cost-
effective. Each probability is calculated as a proportion of
1000 simulations where the incremental cost-effectiveness
ratio (ICER) is less than the ceiling ratio. When the number
of DALYs averted is negative, the ICER is assigned a value
higher than the ceiling ratio to avoid classifying these
simulations as cost-effective. The shaded boxes indicate
the ceiling ratios in international dollars per disability-
adjusted life-year averted. EIR, entomological inoculation
rate; ibpa, infectious bites per annum.
Fig. 5 – Acceptability curves. Each probability is calculated
as a proportion of 1000 simulations where the incremental
cost-effectiveness ratio (ICER) was less than the ceiling
ratio. When the number of disability-adjusted life-years
(DALYs) averted is negative, the ICER is assigned a value
higher than the ceiling ratio to avoid classifying these
simulations as cost-effective. The shaded boxes indicate
the ceiling ratios in international dollars (I$) per DALY
averted. The dashed line corresponds to entomological
inoculation rate (EIR) distribution A, and the solid line
corresponds to EIR distribution B.
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1035V A L U E I N H E A L T H 1 4 ( 2 0 1 1 ) 1 0 2 8 – 1 0 3 8and 97.5 percentiles of the sampled distribution of each parame-
ter, conditional on the mean values of the other parameters. The
lengths of the resultant intervals (for EIR distribution A) are repre-
sented by the horizontal bars in the tornado diagram (Fig. 6) mea-
sure each parameter’s contribution to this uncertainty, and the
ranking in terms of these lengths is indicated in Table 1.
The parameter contributing themost uncertainty is X*h, which
odifies acquired immunity against asexual blood stages. Three
ther parameters, QD, 1 and *F, of the epidemiological model are
lso among the eight that contribute the most uncertainty. These
arameters all relate to the age patterns and outcome of severe
isease in the first years of life. An additional three of the most
mportant sources of uncertainty are characteristics of the vac-
ine, with imprecision in vaccine efficacy contributing less to the
ncertainty in the ICER than that of the vaccine half-life. The third
mportant vaccine characteristic is the extent of homogeneity in
he vaccine effect. The only cost parameter contributing substan-
ially to uncertainty in ICER is the price per dose of vaccine.
The contributions of the different parameters to the uncer-
ainty are similar for both EIR distributions, so we do not show the
ornado diagram for EIR distribution B. The main uncertainty de-
ermining the overall ICER in settings with higher EIRs is whether
he vaccination strategy would have any longer term health ben-
fits, which is not affected by the costs.
EVPI (calculated as described in the Appendix, found at doi:
0.10.106/j.jval.2011.06.004) is substantial with both EIR distribu-
ions (Fig. 7), with both showing peaks close to the ceiling ratio
here half of the parameterizations predict the vaccination to be
ost-effective. At the ceiling ratio of I$207, with EIR distribution A,
he per-capita EVPI is I$4.2, whereas with EIR distribution B, it is
$2.4. As the ceiling ratio increases above this level, the EVPI rap-
dly decreases because cost-effectiveness is ensured. This behav-
or was quite different with hypothetical EIR distributions mim-
cking only areas with stable endemic malaria (not shown). With
hose EIR distributions, cost-effectiveness depends heavily on
hether there are overall health benefits, and over most of the
ange, EVPI increases with the ceiling ratio.
The overall EVPI is obtained by multiplying per-capita EVPI by
he population to which it should be applied. Because the simula-
ions consider the total population (not just those vaccinated), this
opulation is the total of approximately 800 million people living
Fig. 6 – Tornado diagram. Contributions to uncertainty with
bars correspond to the interval between the incremental cos
the 2.5 and 97.5 percentiles of the sampled distribution of th
values. Only the 14 parameters with the greatest contributionmalaria endemic areas of SSA.Multiplying this by the per-capitaVPI at the ceiling ratio of I$207 per DALY gives a value of more
han I$1.9 billion for the total EVPI assuming EIR distribution B and
$3.3 billion for EIR distribution A.
Discussion
Substantive issues
Previous analyses of this epidemiological model all suggested that
pre-erythrocytic malaria vaccines, introduced via the EPI, will be
more effective and cost-effective in lower transmission settings
[4–8], but these did not consider very low transmission settings,
where the burden of disease limits the potential benefits of vacci-
nation. This is the first analysis that combines this information
with a model for the distribution of transmission intensities
across SSA.
mological inoculation rate distribution A. The horizontal
ectiveness ratios (ICERs) predicted from the regression at
rameters, with the other variables held at their central
o uncertainty are included.
Fig. 7 – Expected value of perfect information (EVPI). EVPI
capita of the total population. The shaded boxes indicate
the ceiling ratios in international dollars per disability-
adjusted life-year (I$/DALY) averted. The dashed line
corresponds to entomological inoculation rate distribution
A, and the solid line corresponds to entomologicalento
t-eff
e pa
ns tinoculation rate distribution B.
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be very unlikely to have been cost-effective in the conditions prev-
alent in Africa a few years ago when the population was predom-
inantly rural andmany people were exposed to high EIRs. In these
circumstances, an EPI vaccination program would probably have
little or no benefit and thus never be cost-effective irrespective of
the ceiling ratio. The main reason for this is that a partially effec-
tive vaccinewill delaymorbid episodes, but if transmission is high
enough, susceptible individuals will fall ill eventually. Because the
case fatality rates used in thesemodels increasewith age over part
of the age range [12], delaying episodes sometimes even results in
slightly increased numbers of simulated deaths. The incidence of
malaria, however, is decreasing inmany areas [43,44], and there is
optimism about further major reductions, partly as a result of in-
creasing coverage of vector control, but also because of urbaniza-
tion, which generally reduces malaria transmission [45,46]. The
proportion of African populations living with high EIRs where
RTS,S will not be cost-effective has already decreased and may
well continue to do so.
The uncertainty in the distribution of EIRs, which is not con-
sidered by our formal analysis of EVPI, is therefore a critical deter-
minant of uncertainty in cost-effectiveness, and the value of geo-
graphic data on transmission intensity, if used to precisely target
vaccination, would dwarf the resources needed to collect it. How-
ever, it is not realistic to obtain precise boundaries of where de-
ployment would be cost-effective because only broad-brush indi-
cations of geographic patterns of transmission are available.
Malaria Indicator Surveys [47,48], now being carried out in many
African countries, are important sources of prevalence data, but
these provide only very imprecise and time point–specific esti-
mates of transmission, even when supplemented by case inci-
dence and/or serological [49] data and analyzedwith geostatistical
methods [25] to give high spatial resolution maps. Some degree of
elective deployment, for instance, by deploying vaccine preferen-
ially in areas with established vector control, would be feasible and
hould be considered. Tailoring implementation to transmission in-
ensity at high spatial resolution, however, may be unrealistic.
The simulations reported in this article assume perfect mixing
f mosquito populations feeding on a host population of 100,000
eople. This is very likely a reasonable approximation across
uch of rural SSA; however, in cities and areas with weaker vec-
ors, lowermosquitomobility is likely to lead to highly focal trans-
ission. Additional analyses will consider alternative structures
f the vector population. Further simulation and cost-effective-
ess analyses should also consider vaccinating older children or
ven adults. The additional health benefits would be greater in
ery low transmission settings [5] where herd immunity could be
mportant even with a leaky vaccine, but costs would also be
reater, so the cost-effectiveness is not obvious. Costs and cost-
ffectiveness of a wide range of feasible vaccine deployment op-
ions should be evaluated, although administrative constraints
ill inevitably limit the extent to which policies can be fine-tuned
o local conditions.
Deployment of RTS,S outside SSA should also be considered.
lthough SSA accounts for 91% of P. falciparum malaria cases
orldwide [25,44], the WHO Southeast Asia Region may also be a
riority area because 1.2 billion people are at risk of malaria there.
nly approximately 40% of cases there are P. falciparum [50] and
he levels of transmission are much lower than in Africa, but in
any areas may be within the range where RTS,S use would be
ost-effective.
A further source of uncertainty that hasnot been consideredhere
s themodel structure. A recent analysis of an ensemble of different
odels suggests that the effectiveness predictions and the general
attern of dependence on EIR are rather insensitive to key assump-
ions about heterogeneity inmalaria in the population and about the
uration of natural immunity embodied in the epidemiological aodel (unpublished results). Despite the exclusion of uncertainty
bout the EIR distribution and the model structure from the anal-
sis, the EVPI remains substantial, with the main contributors to
ncertainty being specific parameters of the epidemiological
odel and characteristics of the vaccine that have not been as-
essed in trials.
At low EIR, the cost-effectiveness clearly also depends to a
arge extent on the cost per dose of the vaccine [7,8], but the re-
aining cost parameters are unimportant as sources of uncer-
ainty, presumably because they are rather small contributors to
he overall cost. This implies that our reliance on cost data from
anzania does not limit the generalizability across countries be-
ause cost per dose will be set centrally. At high EIR, even the cost
er dose is unimportant because the key uncertainty is whether
here will be any overall effectiveness at all.
The main characteristics of the vaccine effect that contribute
ubstantial uncertainty are the duration of protection and the het-
rogeneity in vaccine effects. These are more important than the
mprecision in the estimate of average efficacy of a complete
ourse of vaccination for which trial results provide a reasonably
arrow interval. The efficacy of incomplete courses of vaccination
s not an important source of uncertainty in the model, very likely
ecause of the assumption of high completion rates of the full
ourse of vaccination. The duration of protection is essentially
nknown. Previous simulations suggest that the half-life of the
accine effect needs to be at least 2 to 3 years for effectiveness to
e worthwhile [4,5]. It is also very unclear whether the vaccine
rotects some hosts almost completely and others not at all, al-
hough clearly no one is completely protected. A vaccine that com-
letely protects a subset of the population would be preferable to
ne with more equal efficacies [4].
None of this analysis directly addresses questions of afford-
bility or the feasibility of integration with the health system. The
CERs for RTS,S need to be considered in the context of those of
ther interventions thatmay compete for resources. The EVPI sug-
ests that reducing the uncertainties in the analysis would be a
ery good buy, but the dollar values of total EVPI are greater than
he annual global budget formalaria interventions. There is a need
or analysis of the implications of severe resource constraints for
he interpretation of EVPI.
Methodological issues
Population models of the epidemiological effects were used,
rather than cohort models, because of the need to consider indi-
rect protection of unvaccinated people (herd immunity). The pre-
vious analyses [4,5] suggested that herd immunity effects of RTS,S
introduced via the EPI will be negligible, but dynamic models that
allow for population effects on transmission will be essential for
further analyses that consider mass vaccination strategies or con-
comitant application of other interventions, such as vector con-
trol, and for comparisonwith cost-effectiveness of other interven-
tion strategies. There are substantive issues regarding how and
whether to incorporate discounting and effects of population
growth into such models. Discount rates of 3% [31] or even higher
[51] for the SSA context have been proposed. Discounting of the
health benefits and costs by the time of the event since the start of
the program would improve ICERs because the effectiveness, cu-
mulated over time, is higher shortly after the start of the program
and falls off as deferred events occur in older children [4,5]. The
rationale for such discounting is unclear, however. The uncer-
tainty in the extent of such rebound effects is, in principle, already
captured by the probabilistic sensitivity analysis.
A clear limitation of the analysis is that the parameters of the
epidemiological model are sampled independently of each other
despite correlations in the fitted values. Therefore, no interpreta-
tion is offered of the ranking of these parameters in Figure 6. The
nalysis could not consider all possible parameters that might
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1037V A L U E I N H E A L T H 1 4 ( 2 0 1 1 ) 1 0 2 8 – 1 0 3 8vary. In particular, the contributions of stochastic variation or of
uncertainty in coverage of either vaccination or treatment were
not considered. High levels of vaccine coverage may seem un-
likely, considering low coverage of other malaria interventions
[52], but vaccination coverage in many countries [53] is substan-
tially higher than those of other interventions, so the point values
used for vaccination coverage are probably optimistic but reason-
able.
The analysis assumes that the objective of health planners is to
make decisions consistent with maximizing health outcomes, as
measured by DALYs, from available resources. The DALY is a stan-
dard, although somewhat controversial [54,55], outcomemetric in
economic evaluations of interventions in low-income settings
[56,57]. Because most of the burden of disease frommalaria arises
fromprematuremortality, not disability,wewould anticipate sim-
ilar results if ICERs were calculated based on quality-adjusted life-
years or on numbers of deaths. Other relevant considerations not
considered here include effects on the capacity to implement
other interventions [58], avoidance of catastrophic health expen-
iture [59], notions of regret, and decision maker attitudes toward
isk [60].
Conclusions
Cost effectiveness of RTS,S will be maximal in low endemicity
settings. Selective introduction where transmission has been re-
duced would be most efficient. EVPI is substantial because of un-
certainty in vaccine cost, in parameters of the epidemiological
model (hence in the ICER/EIR relationship), and in the variability in
vaccine efficacy. Decisions to deploy RTS,S need to consider af-
fordability and integration with the health system as well as cost-
effectiveness. Strengthening monitoring to provide up-to-date in-
formation on local endemicity and thus guide vaccine deployment
would be a highly efficient use of resources.
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